the aid library

LIST OPTIONS

Filter

10292

About Leishmaniasis

Centers for disease control and prevention CDC (2020) C_CDC

Leishmaniasis is a parasitic disease that is found in parts of the tropics, subtropics, and southern Europe. Leishmaniasis is caused by infection with Leishmania parasites, which are spread by the bite of infected sand flies. There are several different forms of leishmaniasis in people. The most com... more

External Link

Manufacturing Facility Assessment Toolkit
recommended

Centers for Disease Control and Prevention CDC (2020) CC

Tools and resources for occupational safety and health professionals and state and local public health officials assessing manufacturing facilities. Occupational safety and health professionals and state and local public health officials can use these tools to assess coronavirus disease 2019 (COVID... more

Download (171)

View PDF (219)

Monkeypox multi-country outbreak. Rapid Risk Assessment

European Centre for Disease Prevention and Control (ECDC) (2022) C2

Cases of monkeypox (MPX) acquired in the EU have recently been reported in nine EU Member States (Austria, Belgium, France, Germany, Italy, Portugal, Spain, Sweden, and the Netherlands). Monkeypox (MPX) does not spread easily between people. Human-to-human transmission occurs through close contact ... more

Download (301)

View PDF (308)

Situational Analysis Report on Antimicrobial Resistance in Pakistan

The Center for Disease Dynamics, Economics & Policy CDDEP (2016) C2

Pakistan Global Antibiotic Resistance Partnership (GARP) was formed in the wake of international and national efforts for AMR curtailment. A group of experts from microbiology, infectious diseases and veterinary medicine formed a core group at the organizational meet... more

Download (186)

View PDF (245)

African Union AMR Landmark Report: Voicing African Priorities on the Active Pandemic

Africa Center for Disease Control and Prevention (2024) CC

Antimicrobial resistance (AMR) has emerged as a leading cause of death in the African region, surpassing fatalities from malaria, HIV, and TB. In response to this critical threat, the region has adopted the AMR Global Action Plan and the African Union Framework for Antimicrobial Resistance Control 2...020 – 2025, which is tailored to meet the specific needs of African nations through a coordinated approach. While most countries in the region have developed and prioritized National Action Plans (NAPs) to tackle AMR, the overall response remains inadequate given the magnitude of the threat, which endangers human, animal, environmental, aquatic, and plant health. Africa bears a significant burden of infectious diseases, accounting for approximately 95% of malaria deaths, 70% of people living with HIV, and 25% of TB deaths globally. In 2019, AMR was linked to approximately 55,000 deaths from HIV, 30,000 from malaria, and 255,000 overall. Major drivers of AMR in the region include the overuse and misuse of antimicrobials in human and food systems, migration, suboptimal vaccination rates, and environmental contamination from hospital and pharmaceutical effluents. Additionally, there is a lack of access to quality-assured antimicrobials and diagnostics, compounded by inadequate knowledge about AMR. Unlike high-income countries, where indiscriminate antimicrobial use is the primary factor driving AMR, African countries face additional challenges, including a lack of access to clean and safe water, poor Water, Sanitation, and Hygiene (WASH) programs, inadequate infection prevention measures, and suboptimal vaccinations for preventable diseases. One in three hospitals in the region lacks clean, safe running water, and one in eight people defecate openly due to inadequate sanitation. Investments in WASH, infection prevention, and biosecurity could save approximately 700,000 lives annually. Addressing AMR in Africa requires a comprehensive, multi-sectoral approach involving the entire society. Sustainable access to antimicrobials, including antibiotics, vaccines, and therapeutics, is crucial, as lack of access leads to more morbidity and mortality than AMR itself. Support for the region should focus on preventing infections, strengthening health and food systems, developing human resources, ensuring sustainable access to diagnostics and therapeutics, and investing in laboratory infrastructure to support surveillance and data generation. more

Download (131)

View PDF (119)

Antimicrobial Resistance Surveillance Guidance for the African Region

Africa Center for Disease Control and Prevention (2024) CC

Antimicrobials are medicines, including antibiotics, antivirals, antifungals, and antiparasitics, that are used to prevent and treat infections in humans, animals, and plants. Antimicrobial Resistance (AMR) arises when bacteria, viruses, fungi, and parasites no longer respond to these medicines, ren... more

External Link

Situation Analysis: Antibiotic use and resistance in South Africa

The Center for Disease Dynamics, Economics & Policy CDDEP (2011) C2

South Africa has faced many challenges over the past two decades, accomplishing profound positive changes in the social structure and government of the nation. This has not yet fully translated into better health for the population, however, particularly the poorest segment. In fact, the p... more

Download (771)

View PDF (1410)

Zika virus and safety of substances of human origin – A guide for preparedness activities in Europe

European Centre for Disease Prevention and Control (2016) CC

The objective of this document is to guide the preparation and implementation of national preparedness plans for the safety of substances of human origin during outbreaks of Zika virus infection, both in affected and non-affected areas.

Download (167)

View PDF (215)

Towards One Health preparedness: expert consultation 11–12 December 2017

European Centre for Disease Prevention and Control ECDC (2018) CC

Climate change, increasing population densities, and intensified globalisation in trade, travel and migration are among the most important factors shaping the 21st century. Each impacts upon population health and the risk of infectious disease, particularly those originating at the human-animal-envi... more

External Link

Handbook on TB laboratory diagnostic methods in the European Union

European Centre for Disease Prevention and Control (2016) C1

The aim of this handbook is to provide network members and other laboratories involved in the diagnosis of tuberculosis, with an agreed list of key diagnostic methods and their protocols in various areas of TB diagnosis, ranging from microbiological diagnosis of active TB to the diagnosis of latent ... more

External Link

Rabies Clinical and Laboratory Diagnosis Advisory

Division of Public Health Surveillance and Response National Institute for Communicable Diseases (NICD) (2022) CC

Rabies is a fatal viral disease, but is preventable in humans. The rabies virus is transmitted to humans through virus-laden saliva from a rabid animal, mostly dogs. The virus is shed in the saliva of an infected animal and can be introduced into another body through bites, scratches and any other ... more

External Link

Fexinidazole for Human African Trypanosomiasis, the Fruit of a Successful Public-Private Partnership.

Bernhard, S.; Kaiser, M.; Burri, C.; Mäser, P. Diseases (2022) CC

After 100 years of chemotherapy with impractical and toxic drugs, an oral cure for human African trypanosomiasis (HAT) is available: Fexinidazole. In this case, we review the history of drug discovery for HAT with special emphasis on the discovery, pre-clinical development, and operational challenge... more

External Link

Factsheet for the general public - Antimicrobial resistance

European Centers for Disease Control and Prevention ECDC (2019) C2

Antibiotics, also known as antimicrobial drugs, are medicines that can kill or inhibit the growth of bacteria to cure infections in people, animals and sometimes plants. Antibiotics are medicines for bacterial infections (such as pneumococcal pneumonia or staphylococcal bloodstream infections); anti... more

Download (190)

View PDF (185)

Déclaration sur l’utilisation de l’ivermectine pour la COVID-19

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C1

L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement ... more

External Link

Occupational exposures to Ebola virus in Ebola treatment center, Conakry, Guinea

Savini H, Janvier F, Karkowski L, et al. Centers for Disease Control and Prevention (2017) C_CDC

Emerg Infect Dis. 2017 Aug (Accessed July 18,2017) Abstract: We report 77 cases of occupational exposures for 57 healthcare workers at the Ebola Treatment Center in Conakry, Guinea, during the Ebola virus disease outbreak in 2014-2015. Despite the high incidence of 3.5 occupational exposures/healt... more

Download (130)

View PDF (156)

Action Protocol for Enhanced SARI and ILI Surveillance for COVID-19 in Africa

African Union; Africa CDC Centres for Disease Control and Prevention (2020) C2

March 2020 The number of African Union Member States reporting COVID- 19 cases is increasing and there is a likelihood of community transmission. The WHO recently modified the COVID-19 suspect case definition to include severe acute respiratory infection and advises testing of all severe acute res... more

External Link

Self-Study Modules on Tuberculosis

Centers for Disease Control and Prevention CDC (2014) C_CDC

The CDC Self-Study Modules on Tuberculosis are a series of nine educational modules divided into two courses. The first course (Modules 1–5) provides fundamental information about tuberculosis, while the second course (Modules 6–9) offers more specific program-related details. These modules are ... more

Download (313)

View PDF (245)

The State of the World’s Antibiotics Report 2021

Siriam, A.; et al. The Center For Disease Dynamics, Economics & Policy CDDEP (2021) CC

A Global Analysis of Antimicrobial Resistance and Its Drivers. Since the first State of the World’s Antibiotics report in 2015, antimicrobial resistance has leveled off in some high-income countries but continues to rise in many low- and middle-income countries (LMICs), where access to antibiotic... more

Download (103)

View PDF (94)

Mpox Testing Strategy - November 2024

Africa Center for Disease Control and Prevention (2024) CC

Mpox is an emerging zoonotic disease caused by the mpox virus, a member of the Orthopoxvirus genus closely related to the variola virus that causes smallpox. Mpox was first discovered in 1958 when outbreaks of a pox-like disease occurred in monkeys kept for research. The first human case was recorde...d in 1970 in the Democratic Republic of the Congo (DRC) during a period of intensified effort to eliminate smallpox and since then the infection has been reported in a number of African countries. Mpox can spread in humans through close contact, usually skin-to-skin contact, including sexual contact, with an infected person or animal, as well as with materials contaminated with the virus such as clothing, beddings and towels, and respiratory droplets in prolonged face to face contact. People remain infectious from the onset of symptoms until all the lesions have scabbed and healed. The virus may spread from infected animals through handling infected meat or through bites or scratches. Diagnosis is confirmed by polymerase chain reaction (PCR) testing of material from a lesion for the virus’s DNA. Two separate clades of the mpox virus are currently circulating in Africa: Clade I, which includes subclades Ia and Ib, and Clade II, comprising subclades IIa and IIb. Clade Ia and Clade Ib have been associated with ongoing human-to-human transmission and are presently responsible for outbreaks in the Democratic Republic of the Congo (DRC), while Clade Ib is also contributing to outbreaks in Burundi and other countries. In 2022‒2023 mpox caused a global outbreak in over 110 countries, most of which had no previous history of the disease, primarily driven by human-to-human transmission of clade II through sexual contact. In just over a year, over 90,000 cases and 150 deaths were reported to the WHO. For the second time since 2022, mpox has been declared a global health emergency as the virus spreads rapidly across the African continent. On 13 Aug 2024, Africa CDC declared the ongoing mpox outbreak a Public Health Emergency of Continental Security (PHECS), marking the first such declaration by the agency since its inception in 2017.7 This declaration empowered the Africa CDC to lead and coordinate responses to the mpox outbreak across affected African countries. On August 14, 2024, the WHO declared the resurgence of mpox a Public Health Emergency of International Concern (PHEIC) emphasizing the need for coordinated international response. As of August 2024, Mpox has expanded beyond its traditional endemic regions, with new cases reported in countries including Sweden, Thailand, the Philippines, and Pakistan. Sweden has confirmed its first case of Clade 1 variant, which has been rapidly spreading in Africa, particularly in DRC. The emergence of this new variant raises concerns about its potential for higher lethality and transmission rates outside Africa. more

Download (275)

View PDF (256)

Тестування на туберкульозну інфекцію та скринінг на туберкульоз серед біженців, які прибувають до країн Європи з України

European Centre for Disease Prevention and Control ECDC (2022) C1

7 April 2022. Aimed at national policymakers, public health and healthcare planners, staff working in reception centres, and healthcare staff caring for displaced persons, the information note concludes that universal testing of incoming refugees from Ukraine for tuberculosis (TB) infection is not r... more

Manufacturing Facility Assessment Toolkit recommended

Manufacturing Facility Assessment Toolkit
recommended